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resources were derived from public sources. One and two-way sensitivity analy-
ses were performed for key input variables. Budget impact analysis extrapolates 
results of the (CM), using prevalence data, to a health plan with 1 million covered 
lives. An alternate time-dependent model addresses the impact associated with 
the sequencing of diagnostic tests. Results: The CM model predicts a base-case 
savings of $280 per patient for the diagnostic pathway that includes the novel IBS 
diagnostic blood panel. Sensitivity analyses predict a range of cost savings of $120 
- $439. Budget impact analysis predicts a base case savings of $1,080,232 to the 
plan or $0.09 on a per member per month basis for the diagnostic pathway with 
the novel IBS diagnostic blood panel. The time dependent model indicates that 
the potential cost savings associated with the novel IBS blood test are attenuated 
over time. ConClusions: Current literature suggests that extensive diagnostic 
testing to diagnose IBS is not necessary. This economic evaluation indicates that 
the inclusion of a novel IBS diagnostic blood panel in the diagnostic process has 
the potential for significant cost savings due to the avoidance of unnecessary 
testing.
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objeCtives: Irritable bowel syndrome presents a significant burden to patients 
and to the healthcare system in Mexico. An IBS diagnosis is based on Rome crite-
ria; however, laboratory tests and diagnostic procedures are required to exclude 
organic conditions such as inflammatory bowel disease (IBD). A new IBS diagnostic 
blood panel has been developed which tests for the presence of two biomarkers 
associated with IBS-D. This analysis assesses the cost impact to the Mexican private 
practice. Methods: Budget impact analysis (BIA) was based on a cost-minimization 
(CM) decision model developed to compare the costs associated with two possible 
diagnostic pathways: (1) diagnostic pathway with a new IBS diagnostic blood panel 
and (2) exclusionary diagnostic pathway (i.e. standard of care) and applied to the 
Mexican population. Model structure was based on current literature and guidance 
from IBS expert clinicians. Direct medical expenses for laboratory tests, diagnos-
tic procedures and visit costs were included in Mexican pesos and weighted by 
utilization rates provided by practicing gastroenterologists in private practice in 
Mexico. The indirect cost estimate was based on the literature and only included 
absenteeism, adjusted for per capita income. The base case assumes that 75% of 
patients who receive a positive test result will proceed to IBS-D treatment. For the 
BIA, it is assumed that 30% of IBS-D patients will seek care, and clinicians use the 
test for 50% of patients presenting with IBS-D symptoms. Results: The CM model 
predicts per patient savings with the IBS diagnostic panel of Mex$1,688 (Mex$35,019 
vs. Mex$36,707). Cost neutrality occurs if 44% of the “positive test” patients receive 
IBS-D treatment. The BIA predicts a net savings to the Mexican healthcare system 
of Mex$794,158,235. ConClusions: Inclusion of a novel IBS diagnostic blood panel 
in the diagnostic process has the potential for significant cost savings due to the 
avoidance of downstream testing.
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objeCtives: DuoResp® Spiromax® (budesonide + formoterol fumarate dihydrate) 
is a fixed-dose combination (FDC) of inhaled corticosteroid (ICS) + long-acting beta 
agonist (LABA) in a novel dry powder inhaler (DPI). A five year economic model was 
developed from a healthcare payer perspective to assess the impact of potentially 
improved inhalation technique on unscheduled healthcare events and costs, when 
switching adult patients with persistent asthma and chronic obstructive pulmonary 
disease (COPD) from market-leading DPIs in Spain – Symbicort® Turbuhaler® and 
Seretide® Accuhaler® – to DuoResp® Spiromax®. Methods: The eligible patient 
population was estimated from current confirmed Spanish asthma and COPD diag-
nosis rates, with the proportion receiving FDCs based on market research data. 
Costs of unscheduled healthcare events were taken from publicly available Spanish 
sources. The frequency of poor inhalation technique with the market-leading DPIs, 
and the associated increased risk of unscheduled healthcare events, were taken 
from a large (n= 1,664) cross-sectional Italian study. The hypothetical reduction in 
poor inhalation technique with DuoResp® Spiromax® was an assumption based 
on the novel attributes of the Spiromax® inhaler. Results: The model estimated 
that 266,657 adult patients used Symbicort® Turbuhaler® and 296,905 Seretide® 
Accuhaler® – and were therefore eligible to receive DuoResp® Spiromax® – annu-
ally, with 115,996 (43.5%) and 102,432 (34.5%) exhibiting poor inhalation technique, 
respectively. The total cost of unscheduled healthcare events associated with poor 
inhalation technique was estimated to be € 11.54 million annually. Assuming a hypo-
thetical uptake of DuoResp® Spiromax® increasing from 6% in year 1 to 18% in year 
4 and 5, an estimated 51,633 unscheduled healthcare events were avoided due to 
the predicted improvement in inhalation technique with DuoResp® Spiromax® 
compared with other DPIs, resulting in cost savings totalling € 4.79 million over five 
years. ConClusions: Introducing DuoResp® Spiromax® may reduce the occur-
rence of unscheduled healthcare events compared with market-leading DPIs, poten-
tially resulting in cost savings.
treatment. ConClusions: Inclusion of a novel IBS diagnostic blood panel in the 
diagnostic pathway has the potential for significant cost savings due to the avoid-
ance of unnecessary testing.
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objeCtives: UK guidelines for the diagnosis of IBS in patients who meet diagnos-
tic criteria include FBC, ESR, C - reactive protein and testing for coeliac disease to 
exclude other diseases. Despite these recommendations, referral for procedures 
such as flexible sigmoidoscopy, colonoscopy and ultrasound scanning continue 
and in the majority of this patient group, are considered to be unnecessary, sub-
sequently placing an increased cost burden to National Health Services (NHS). A 
novel IBS diagnostic blood panel has been developed which tests for the presence 
of two biomarkers associated with IBS-D. This analysis estimates the potential 
cost impact to the NHS by introducing this test into the diagnostic pathway of 
IBS. Methods: Budget impact was based on a cost-minimization model to com-
pare the costs associated with two possible diagnostic pathways: (1) with a novel 
IBS diagnostic blood panel and (2) exclusionary pathway and applied to the UK 
population 18-65yrs old. Model structure was based on current literature/ guidance 
from IBS expert. Direct medical expenses include, labs, diagnostic procedures, 
visits in £ and weighted by utilization provided by a practicing gastroenterologist 
in the UK. Results: Gastroscopy, flexible sigmoidoscopy, and colonoscopy were 
the most common diagnostic (instrumental) procedures reported with estimated 
utilization rates of 55%, 55% and 35%, respectively. Corresponding charges were 
£200, £400 and £400, respectively. Net savings in the base case of £57 favored 
the IBS diagnostic blood panel pathway (assumes 75% of test positive patients 
receive IBS-D treatment) vs the exclusionary pathway. If clinicians use the test 
50% of the time for the 30% of the estimated 446,382 people who might have IBS-D 
who seek treatment, net potential savings to NHS is £12,721,891. ConClusions: 
Inclusion of a novel IBS diagnostic blood panel in the diagnostic pathway has 
the potential for significant cost savings due to the avoidance of unnecessary 
testing.
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objeCtives: Current guidelines recommend a positive strategy based on symp-
tom criteria without alarm features vs diagnostic exclusion which includes several 
laboratory and diagnostics procedures to exclude other organic conditions. A novel 
IBS diagnostic blood panel tests for the presence of two biomarkers associated with 
IBS-D which can complement the positive strategy. This analysis assesses the cost 
impact to the Danish healthcare system by introducing this test into the diagnostic 
pathway. Methods: A budget impact model was based on a cost-minimization 
decision model developed to compare the costs associated with two possible diag-
nostic pathways: (1) diagnostic pathway with a novel IBS diagnostic blood panel and 
(2) exclusionary diagnostic pathway and applied to the Danish population 18-65yrs 
old. Model structure was based on current literature and guidance from IBS expert 
clinicians. Direct medical expenses for laboratory tests, diagnostic procedures and 
visit costs were included in Danish Krone and weighted by utilization rates esti-
mated by a practicing gastroenterologist in Denmark. Indirect cost only included 
time off work based on a published Danish study. Results: Sigmoidoscopy, colo-
noscopy and SBFT were the most common diagnostic procedures reported with 
estimated utilization rates of 35%, 35% and 15%, respectively. Corresponding charges 
were kr4819, kr4819 and kr1861, respectively. Estimated total base case charges 
for the IBS diagnostic blood panel pathway (assumes 75% of test positive patients 
receive IBS-D treatment) vs the exclusionary pathway were kr11,237 vs kr12,284, 
respectively. If clinicians use the test 50% of the time for the 30% of the estimated 
57,490 people who might have IBS-D who seek treatment, net savings to the Danish 
healthcare system is kr30,095,980. Cost neutrality occurs if 37% of the “test positive” 
patients seek IBS treatment. ConClusions: This economic evaluation indicates 
that a positive strategy may be further enhanced with a novel IBS diagnostic blood 
panel leading to significant cost savings.
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objeCtives: The diagnosis of diarrhea predominant irritable bowel syndrome 
(IBS-D) is based on clinical presentation and several laboratory and diagnostic pro-
cedures to exclude other organic conditions. A novel IBS diagnostic blood panel has 
been developed which tests for the presence of two biomarkers associated with 
IBS-D. This study assesses the cost implications associated with introducing this 
test into the diagnostic pathway. Methods: A cost-minimization (CM) decision 
tree model was constructed to compare the costs associated with two possible 
diagnostic pathways: (1) diagnostic pathway with novel IBS diagnostic blood panel 
and (2) exclusionary diagnostic pathway (i.e. standard of care). Model structure 
was based on current literature and guidance from IBS expert clinicians. Costs for 
